Antibody-based therapeutics with enhanced adcc activity

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 39/395 (2006.01) A61K 38/16 (2006.01) A61K 47/48 (2006.01) A61P 31/00 (2006.01) A61P 35/00 (2006.01) A61P 37/00 (2006.01) C07K 16/00 (2006.01) C12P 21/08 (2006.01) C07K 16/18 (2006.01) C07K 16/30 (2006.01)

Patent

CA 2626556

Methods for producing antibody-based therapeutics with enhanced ADCC activity are disclosed. The enhanced ADCC activity is attributed to oligomannose- type N/-glycans on the antibodies and Fc fusion proteins of the invention. Also disclosed are methods of using such antibody-based therapeutics for targeted killing of cells in a mammal, including therapeutic methods of treating cancers, autoimmune diseases and other diseases.

L'invention porte sur des méthodes d'élaboration de thérapies à base d'anticorps à activité ADCC renforcée laquelle est attribuée aux N/-glycans de type oligomannose des anticorps et aux protéines de fusion de l'invention. L'invention porte également sur des méthodes d'utilisation desdites thérapies pour la destruction ciblée de cellules de mammifères, y compris des méthodes de traitement de cancers, de maladies auto-immunes, et autres.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Antibody-based therapeutics with enhanced adcc activity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibody-based therapeutics with enhanced adcc activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody-based therapeutics with enhanced adcc activity will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1522168

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.